Combination of photodynamic therapy and specific immunotherapy efficiently eradicates established tumors

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1459-1468

  Kleinovink, Jan Willem ^a   Van Driel, Pieter B ^a,b   Snoeks, Thomas J ^a   Prokopi, Natasa ^a   Fransen, Marieke F ^a   Cruz, Luis J ^a   Mezzanotte, Laura ^a   Chan, Alan ^b   Löwik, Clemens W ^a   Ossendorp, Ferry ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PERCUROS B V   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREMACHLORIN; CANCER VACCINE; PHOTOSENSITIZING AGENT; SYNTHETIC LONG PEPTIDE; UNCLASSIFIED DRUG; SUBUNIT VACCINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; LYMPHOMA; METASTASIS; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; RMA CELL LINE; TC 1 CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; TUMOR OUTGROWTH; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; MICE; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TUMOR BURDEN; VACCINES, SUBUNIT;

EID: 84962274743     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0515     Document Type: Article

References (47)

1. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-60.
2. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 2011;17: 343-50.
3. Corradin G, Kajava AV, Verdini A. Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age. Sci Transl Med 2010;2:50rv3.
4. Tomita Y, Nishimura Y. Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4 and CD8 T cells. Oncoimmunology 2013;2:e25801.
5. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
6. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de GJ, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012;72: 1081-91.
7. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8.
8. Hu J, Budgeon LR, Balogh KK, Peng X, Cladel NM, Christensen ND. Longpeptide therapeutic vaccination against CRPV-induced papillomas inHLAA2.1 transgenic rabbits. Trials Vaccinol 2014;3:134-42.
9. Zhang L, Chen J, Song X, Wen W, Li Y, Zhang Y, et al. Cancer/testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model. Oncol Res 2014;21: 193-200.
10. Kenter GG, Welters MJ, Valentijn AR, LowikMJ, Berends-van derMeer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
11. Kenter GG, Welters MJ, Valentijn AR, LowikMJ, Berends-van derMeer DM, Vloon AP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-77.
12. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013;11:88.
13. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011;61: 250-81.
14. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380-7.
15. Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010;15:1050-71.
16. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012;31:1062-79.
17. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010;1805:53-71.
18. Korbelik M, Zhang W, Merchant S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother 2011;60:1431-7.
19. Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR. Stimulation of antitumor immunity by photodynamic therapy. Expert Rev Clin Immunol 2011;7:75-91.
20. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and antitumour immunity. Nat Rev Cancer 2006;6:535-45.
21. Castano AP, Liu Q, Hamblin MR. A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy. Br J Cancer 2006;94:391-7.
22. Mroz P, Szokalska A, Wu MX, Hamblin MR. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One 2010;5:e15194.
23. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010;46:216-26.
24. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 2009;15:4460-6.
25. Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer 2007;96:1839-48.
26. Douillard S, Olivier D, Patrice T. In vitro and in vivo evaluation of Radachlorin(R) sensitizer for photodynamic therapy. Photochem Photobiol Sci 2009;8:405-13.
27. Douillard S, Lhommeau I, Olivier D, Patrice T. In vitro evaluation of Radachlorin sensitizer for photodynamic therapy. J Photochem Photobiol B 2010;98:128-37.
28. Uzdensky AB, Dergacheva OY, Zhavoronkova AA, Reshetnikov AV, Ponomarev GV. Photodynamic effect of novel chlorin e6 derivatives on a single nerve cell. Life Sci 2004;74:2185-97.
29. van Leeuwen-van ZF, van Driel PB, Gamm UA, Snoeks TJ, de Bruijn HS, van der Ploeg-van den Heuvel, et al. Microscopic analysis of the localization of two chlorin-based photosensitizers in OSC19 tumors in the mouse oral cavity. Lasers Surg Med 2014;46:224-34.
30. Kochneva EV, Filonenko EV, Vakulovskaya EG, Scherbakova EG, Seliverstov OV, Markichev NA, et al. Photosensitizer Radachlorin(R): Skin cancer PDT phase II clinical trials. Photodiagnosis Photodyn Ther 2010;7:258-67.
31. Ji W, Yoo JW, Bae EK, Lee JH, Choi CM. The effect of Radachlorin(R) PDT in advanced NSCLC: a pilot study. Photodiagnosis Photodyn Ther 2013;10: 120-6.
32. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
33. Bae SM, Kim YW, Lee JM, NamKoong SE, Han SJ, Kim JK, et al. Photodynamic effects of Radachlorin on cervical cancer cells. Cancer Res Treat 2004;36:389-94.
34. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-59.
35. van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber WJ, et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol 2012;189:3397-403.
36. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
37. Mroz P, Vatansever F, Muchowicz A, Hamblin MR. Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res 2013;73:6462-70.
38. zur Hausen H. Viruses in human cancers. Science 1991;254:1167-73.
39. Javier RT, Butel JS. The history of tumor virology. Cancer Res 2008;68: 7693-706.
40. Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, et al. Therapy of human papillomavirus-related disease. Vaccine 2012;30 Suppl 5:F71-F82.
41. Martin-Hirsch PL, Whitehurst C, Buckley CH, Moore JV, Kitchener HC. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet 1998;351:1403.
42. Soergel P, Hillemanns P. Photodynamic therapy for intraepithelial neoplasia of the lower genital tract. Photodiagnosis Photodyn Ther 2010;7:10-4.
43. Park EK, Bae SM, Kwak SY, Lee SJ, Kim YW, Han CH, et al. Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model. Immunology 2008;124:461-8.
44. Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, et al. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res 2008;14:5292-9.
45. Bae SM, Kim YW, Kwak SY, Kim YW, Ro DY, Shin JC, et al. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells. Cancer Sci 2007;98: 747-52.
46. Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A 2008;105:5495-500.
47. Mroz P, Hamblin MR. The immunosuppressive side of PDT. Photochem Photobiol Sci 2011;10:751-8.